



# HflXr mediates a novel antibiotic resistance mechanism 1 2

Mélodie Duval, Daniel Dar, Filipe Carvalho, Eduardo Rocha, Rotem Sorek,  
Pascale Cossart

## ► To cite this version:

Mélodie Duval, Daniel Dar, Filipe Carvalho, Eduardo Rocha, Rotem Sorek, et al.. HflXr mediates a novel antibiotic resistance mechanism 1 2. Proceedings of the National Academy of Sciences of the United States of America , National Academy of Sciences, 2018, 115 (52), pp.13359-13364. 10.1073/pnas.1810555115 . hal-02329775

**HAL Id: hal-02329775**

**<https://hal.archives-ouvertes.fr/hal-02329775>**

Submitted on 23 Oct 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **HflXr mediates a novel antibiotic resistance mechanism**

2

3 Melodie Duval<sup>1,2,3</sup>, Daniel Dar<sup>4</sup>, Filipe Carvalho<sup>1,2,3</sup>, Eduardo P. C. Rocha<sup>5,6</sup>, Rotem Sorek<sup>4</sup>,

4 Pascale Cossart<sup>1,2,3\*</sup>

5

6 1. Département de Biologie Cellulaire et Infection, Institut Pasteur, Unité des  
7 Interactions Bactéries-Cellules, F-75015 Paris, France.

8 2. Inserm, U604, F-75015 Paris, France.

9 3. INRA, Unité sous-contrat 2020, F-75015 Paris, France.

10 4. Department of Molecular Genetics, Weizmann Institute of Science, Rehovot  
11 76100, Israel

12 5. Microbial Evolutionary Genomics, Institut Pasteur, 75015, France.

13 6. CNRS, UMR3525, Paris, 75015, France.

14

15

16 \* to whom correspondence should be addressed : [pascale.cossart@pasteur.fr](mailto:pascale.cossart@pasteur.fr)

17

18 keywords : HflX, *Listeria*, erythromycin, lincomycin, ribo-regulator, ribosome splitting,

19 molecular evolution

20

21

22 **Abstract (less than 250 words, now : 250)**

23

24 Bacteria have evolved a variety of different strategies to overcome the action of  
25 antibiotics, such as drug modification, target mutation and efflux pumps. Recently, we  
26 performed a genome-wide analysis of *Listeria monocytogenes* gene expression after  
27 growth in the presence of antibiotics, identifying genes that are upregulated upon  
28 antibiotic treatment. One of them, *lmo0762*, is a homolog of *hflX*, which encodes a heat  
29 shock protein that rescues stalled ribosomes by separating their two sub-units. To our  
30 knowledge, ribosome splitting has never been described as an antibiotic resistance  
31 mechanism. We thus investigated the role of *lmo0762* in antibiotic resistance. First, we  
32 demonstrated that *lmo0762* is a novel antibiotic resistance gene that confers protection  
33 against lincomycin and erythromycin, and that we renamed *hflXr* (*hflX*-resistance). We  
34 showed that *hflXr* expression is regulated by a transcription attenuation mechanism  
35 relying on the presence of alternative RNA structures and a small ORF containing the  
36 RLR motif, characteristic of macrolide resistance mechanisms. We provide evidence that  
37 HflXr is involved in ribosome recycling in presence of antibiotics. Interestingly, *L.*  
38 *monocytogenes* possesses another copy of *HflX* in the core genome, *lmo1296*, that is not  
39 involved in antibiotic resistance. Phylogenies of this family show several events of gene  
40 duplication and widespread presence of the *lmo0762* family in Firmicutes. Overall, this  
41 study highlights a previously unknown antibiotic resistance mechanism, identifying the  
42 *Listeria hflXr* as the first member of a new family of antibiotic resistance genes. The  
43 resistance conferred by this gene is probably of importance in the environment and  
44 within microbial communities.

45

46 **Significance Statement**

47

48 Antibiotics have been widely used to treat infections. However, bacteria have evolved  
49 various antibiotic resistance mechanisms, allowing them to overcome drug exposure  
50 and raising important health issues. Here, we report a new bacterial antibiotic  
51 resistance mechanism, occurring via ribosome splitting and recycling, ensuring efficient  
52 translation even in presence of lincomycin and erythromycin, two antibiotics that block  
53 protein synthesis. This novel mechanism is mediated by a HflX-like protein, encoded by  
54 *lmo0762* in *L. monocytogenes*, whose expression is tightly regulated by a transcriptional

55 attenuation mechanism. This gene increases bacterial fitness in the environment. Our  
56 results raise the possibility that other antibiotic-induced resistance mechanisms remain  
57 to be discovered.

58

59 \body

60 Introduction

61 To treat bacterial infections, the use of bacteriostatic or bactericidal antibiotics  
62 remains the gold standard. These molecules act at many levels of the bacterial  
63 metabolism to prevent replication or to promote death. In the last decade, antibiotic  
64 resistance of pathogenic bacteria has become a major public health concern, and multi  
65 resistant strains have become increasingly difficult to treat. In 2015, the World Health  
66 Organization published an action plan on antimicrobial resistance that aims to ensure  
67 prevention and treatment of infectious diseases with safe and effective medicines.  
68 Beside their use as therapeutics, antibiotics are also found in the environment, since  
69 micro-organisms use them as strategies to compete and survive within microbial  
70 communities, and given that many antibiotic-producing organisms such as *Streptomyces*  
71 *spp* live in the soil [1].

72 To overcome the action of antibiotics, bacteria have evolved a number of  
73 different resistance strategies. Resistance can be intrinsic, i.e. corresponding to a natural  
74 property of the bacteria, such as the presence, in Gram-negative bacteria, of an outer  
75 membrane that protects peptidoglycan from vancomycin [2], or acquired, e.g. gain of  
76 plasmid-mediated antibiotic resistance genes. The resistance mechanisms can be  
77 classified in three major families: those that prevent the drugs from entering the cell or  
78 that actively pump them out of the bacteria, those that inactivate the antibiotic, and  
79 those that modify the target so that it cannot be recognized by the antibiotic[3]. The  
80 genes involved in these mechanisms are often induced in presence of antibiotics, using  
81 various regulatory systems[4]. One of those, called “attenuation”, relies on the presence  
82 of a 5’ regulatory region that folds into alternative RNA structures controlling either  
83 transcription or translation of the resistance gene.

84 *L. monocytogenes* is a food-borne pathogen responsible for listeriosis, a rare but  
85 lethal disease, that affects immunocompromised individuals, as well as pregnant women  
86 and elderly people[5]. Although listeriosis can be efficiently treated with ampicillin and  
87 gentamicin, resistance to various antibiotics, including lincosamides, gentamicin,  
88 ampicillin, streptomycin, erythromycin, kanamycin, rifampicin[6–12] has been reported  
89 in both food and clinical isolates.

90 In a previous analysis[13], we used a novel method “term-seq” to map the 3’ ends  
91 of all RNAs in bacteria grown under various conditions, including in the presence or

92 absence of antibiotics. We discovered a previously unknown antibiotic resistance gene  
93 in *L. monocytogenes* EGDe laboratory strain, *lmo0919*, which is induced in the presence  
94 of lincomycin, an antibiotic that blocks translation by binding to the 70S ribosome in the  
95 peptidyl transfer center, thereby preventing the transpeptidation step[14]. Another  
96 gene, *lmo0762*, is also induced in the presence of lincomycin. This gene is located  
97 downstream of *rli80*, a small RNA that encodes a putative 14 amino-acids open reading  
98 frame (ORF). By sequence comparison, we found that the protein encoded by *lmo0762* is  
99 homologous to *E. coli* and *S. aureus* HflX, GTPase proteins that bind to 70S  
100 ribosomes[15–18] and recycle blocked ribosomes during heat shock in a GTP-  
101 dependent manner[15, 19, 20]. Moreover, HflX was recently described as a RNA helicase  
102 that modulates rRNA conformation of heat-damaged 50S subunits in *E. coli* [21], and  
103 HflX also splits 100S disomes in *S. aureus*[20]. The specific expression activation of  
104 *lmo0762* by sub-lethal doses of antibiotics suggests that this gene is involved in  
105 antibiotic resistance, but to our knowledge, such a mechanism of ribosome splitting has  
106 never been described in the context of antibiotic resistance, and hence *lmo0762*  
107 appeared a new class of antibiotic resistance gene.

108 In this study, we assessed the role of *lmo0762* in antibiotic resistance. We first  
109 confirmed its induction in the presence of lincomycin. By creating deletion and  
110 overexpressing strains, we showed that the gene confers resistance to lincomycin and  
111 erythromycin, two antibiotics that blocks translation. Thus, we renamed it *hflXr*, for *hflX*-  
112 resistance. We analysed its expression regulation, and by combining structure  
113 prediction of *rli80* and analysis of various mutants, we showed that a transcription  
114 attenuation mechanism potentially leading to premature transcription termination  
115 controls *hflXr* expression. This attenuation mechanism relies on the 14-aa ORF encoded  
116 by *rli80* which strikingly contains the arginine-leucine-arginine (RLR) motif, a signature  
117 feature for macrolide resistance gene leader peptides [22]. Moreover, by analysing the  
118 ribosome “profiles” of bacteria grown in the presence of erythromycin, we provide data  
119 suggesting that *Lmo0762* splits blocked 70S ribosome and promotes translation. Finally,  
120 we identified in *L. monocytogenes* another homolog of *hflX*, *lmo1296*, which is not  
121 involved in antibiotic resistance. By analysing the phylogeny of *hflX* genes in  
122 prokaryotes, we found that this duplication happened several times independently in  
123 several major clades of prokaryotes, and that many Firmicutes possess a *hflX* copy  
124 closely related to *hflXr*. Hence, it is tempting to speculate that the mechanism is shared

125 by numerous bacterial species. Overall, these data reveal a new antibiotic resistance  
126 mechanism in bacteria that is probably of importance for survival in the environment  
127 and within microbial communities.

128

## 129 Results

### 130 ***lmo0762* is a new antibiotic resistance gene**

131 In a previous study[13], we analysed the expression profile of all *Listeria* genes in  
132 the presence of sub-inhibitory concentrations of lincomycin, and discovered that  
133 *lmo0762* is induced (Fig. 1A). This gene is located downstream of a small RNA, *rli80*, and  
134 while *rli80* appears to be transcribed in both the absence (black) or the presence  
135 (green) of lincomycin, *lmo0762* is primarily transcribed in the presence of the antibiotic.  
136 This specific upregulation upon antibiotic exposure prompted us to investigate whether  
137 *lmo0762* plays a role in antibiotic resistance. In order to verify *lmo0762* induction by  
138 lincomycin at the protein level, we created a strain in which a Flag tag was introduced at  
139 the C-terminus of the Lmo0762 protein. We extracted total proteins from *Listeria* grown  
140 in BHI in the absence or presence of sub-inhibitory concentration of the antibiotic, and  
141 performed a western blot experiment using an anti-Flag antibody (Fig. 1B left pannel).  
142 EF-Tu was used as a loading control. The results confirmed that in presence of  
143 lincomycin, Lmo0762 is induced.

144 In order to test whether *lmo0762* is an antibiotic resistance gene, we constructed  
145 a mutant strain with a deleted *rli80-lmo0762* region (hereafter named  $\Delta$ *lmo0762*). We  
146 complemented the deletion by reintroducing the *rli80-lmo0762* region under the control  
147 of its native promoter using the pAD integrative plasmid [23] (hereafter named  
148  $\Delta$ *lmo0762-cpt*), and we verified by qRT-PCR that in the complemented strain, *lmo0762* is  
149 induced by lincomycin at a level similar to that of the WT strain (Figure S1). We also  
150 created a strain that overexpresses the gene (see below), that we named *anti-anti*. This  
151 strain constitutively express Lmo0762, which results in an accumulation of the protein,  
152 independently from the presence of antibiotics (Fig S2). We then performed a minimum  
153 inhibitory concentration (MIC) assay on the 4 strains using various antibiotics (Fig 1C,  
154 left panel and Fig S3), and we observed that the  $\Delta$ *lmo0762* strain is more sensitive to  
155 erythromycin than the WT strain or the complemented strain with a 2-fold effect, a  
156 result consistent with effects which have been observed with several macrolide  
157 resistance determinants[24]. Moreover, the overexpressing strain *anti-anti* is more

158 resistant to erythromycin compared to the WT. In order to validate these results, we  
159 confirmed by Western Blot that Lmo0762 protein is also induced in presence of  
160 erythromycin (Fig. 1B right pannel), even though a qRT-PCR analysis showed that the  
161 induction at the transcription level is lower than in presence of lincomycin (Fig. 1D). The  
162 MIC assay did not show increased sensitivity of the *Almo0762* strain compared to the  
163 WT strain for any other antibiotics, although, as shown above, *lmo0762* is induced by  
164 lincomycin. In these conditions, an accumulation of Lmo0762 even seems detrimental  
165 for the survival of the bacteria (*anti-anti* strain). Given that we previously identified  
166 another gene, *lmo0919*, as a lincosamide resistance gene [13], we hypothesized that  
167 *lmo0919* may be masking the effect of the *lmo0762* deletion. Thus, we constructed a  
168 double mutant strain, *Almo0919Almo0762*, that we complemented with *rli80-lmo0762* as  
169 previsouly described (*Almo0919Almo0762-cpt*), and we also introduced the mutation  
170 that overexpresses *lmo0762* (*Almo0919-XXXXXXXXXX*).  
171 WXX (Fig. 1C  
172 right panel and Fig. S3), and strikingly, we found that this double mutant is 4-fold more  
173 sensitive to lincomycin compared to the *Almo0919* strain, and that resistance is restored  
174 in the complemented strain. Moreover, overexpression of Lmo0762 (*Almo0919-XXXXXXXXXX*)  
175 XXXXXXXXXXXXXXXXXXXXXXX) renders the strain more resistant to lincomycin than the *Almo0919*  
176 strain. Overall, we conclude that *lmo0762* is a novel mechanism of antibiotic resistance  
177 to lincomycin and erythromycin.

178

### 179 **Lmo0762 is a HflX homolog**

180 To explore the mode of action of this gene, we searched for homologs of the  
181 protein encoded by *lmo0762* using blastp and hmm protein profiles. This revealed  
182 homologs of HflX in various bacteria (Table S1), including *Staphylococcus aureus*,  
183 *Bacillus subtilis* and *Escherichia coli*. HflX has been described as a heat-shock stress-  
184 response GTPase protein that can split and recycle ribosomes that have become  
185 immobilized due to heat stress[15, 19, 20]. We renamed *lmo0762* to *hflXr*, for *hflX*-  
186 resistance. Surprisingly, we discovered another homolog of *hflX* in *L. monocytogenes*,  
187 *lmo1296* (Table S1). The two proteins encoded from *lmo0762* and *lmo1296* contain a  
188 GTP-binding domain and a 50S binding domain, like all other 8527 homologs of this  
189 family that were found within 8113 genomes (Table S2).



190 In order to decipher whether *lmo1296* also participates to antibiotic resistance,  
191 we first analysed its induction upon antibiotic exposure. We grew the bacteria in  
192 presence and absence of antibiotics, we extracted total RNA and performed qRT-PCR  
193 experiment. The results show weak or no induction of *lmo1296* upon antibiotic exposure  
194 in comparison to *lmo0762* (Fig 1D). Second, we deleted the gene from the EGDe strain  
195 ( $\Delta$ *lmo1296*), and we used this strain to perform MIC assay (Fig 2A). The results showed  
196 no susceptibility for erythromycin, or any other antibiotics tested (Fig S3). We also  
197 created the double deletion strain  $\Delta$ *lmo0762*- $\Delta$ *lmo1296*, and no further susceptibility  
198 could be observed compared with the  $\Delta$ *lmo0762* strain. Finally, we re-introduced the  
199 *lmo1296* gene under the control of *rli80* in the  $\Delta$ *lmo0762* mutant (named  $\Delta$ *lmo0762*-  
200 *cpt1296*, fig. S1A). We controlled by qRT-PCR that in this strain *lmo1296* is induced by  
201 the antibiotic at a similar level compared to *lmo072* in the WT or complemented strain  
202 ( $\Delta$ *lmo0762*-*cpt*) due to *rli80* regulation (Fig S1B), and we tested the strain in a MIC  
203 assay. We observed that unlike the strain  $\Delta$ *lmo0762*-*cpt* the strain  $\Delta$ *lmo0762*-*cpt1296*  
204 remains sensitive to erythromycin. Altogether, these data indicate that *lmo1296* is not  
205 involved in antibiotic resistance.

206 To unravel the evolutionary history of *hflXr* and its homologs, we reconstructed  
207 the phylogeny of *hflX* genes among prokaryotes (Fig. 2B and Fig S4). Strikingly, the  
208 phylogenetic tree shows that *lmo1296* and *lmo0762* are well separated in two large  
209 clades, both containing almost only Firmicutes. This duplication event is probably old,  
210 since it is shared by many bacteria from the clade, and the trees of the two sub-families  
211 coarsely recapitulate the tree of Firmicutes (Fig. S5). Interestingly, other phyla also  
212 harbour a duplication in the *hflX* genes, e.g.  $\alpha$ ,  $\beta$ ,  $\gamma$  and  $\delta$  Proteobacteria and Archaea.  
213 These duplications occurred independently from the one of Firmicutes, highlighting the  
214 importance of *hflX* duplicated genes. The analysis of 163 pan-genomes from bacteria  
215 revealed that the genes of this family, when present, are in the core genome (98% in  
216 >90% of the strains, Fig S6). Finally, the analysis of genetic neighbourhood of the two  
217 sub-families showed much higher conservation for *lmo1296* than for *lmo0762* (Table S3  
218 and S4). Based on these elements, it is tempting to speculate that the ancient duplication  
219 of *hflX* led to two proteins with specialized functions in Firmicutes, explaining why  
220 duplicates co-occur, one of which is involved in antibiotic resistance (*hflXr*). If correct,  
221 this means that other genes of this sub-family may provide antibiotic resistance. Such

222 genes were found in important pathogens, such as *Bacillus cereus*, *Bacillus anthracis*, and  
223 *Clostridioides difficile*.

224

### 225 **HflXr recycles ribosomes upon antibiotic exposure**

226 Ribosome stalling is a phenomenon induced by heat shock that results in halt of  
227 translation. Some antibiotics can also impair translation, and resistance proteins that  
228 remove the antibiotic from the stalled ribosome have previously been described. These  
229 include, tetO, tetM, and ABC-F transporters[25–27]. However, a mechanism by which the  
230 ribosome is split and recycled has not been described in the context of antibiotic  
231 resistance, and could constitute a new class of antibiotic resistance factors.

232 In order to assess this hypothesis, we grew WT and  $\Delta lmo0762$  bacteria in the  
233 presence and absence of antibiotic, and performed a polysome profiling assay. Given  
234 that *lmo0919* may mask the effect of *hflXr* in the presence of lincomycin, we used  
235 erythromycin in this experiment. The results show that in the presence of the antibiotic,  
236 the 70S proportion is higher in  $\Delta lmo0762$  strain compared with a WT strain (Fig. 3),  
237 while in the absence of antibiotics no difference was observed (Fig S7). A similar  
238 experiment has been performed in *Escherichia coli* in the context of heat shock, and the  
239 peak difference obtained in this study is comparable to what we obtained in presence of  
240 erythromycin[19]. Such an accumulation of 70S in absence of *hflXr* show that this gene  
241 participates in ribosome recycling, probably by splitting ribosomes upon antibiotic  
242 exposure, thus recycling them to start new rounds of translation.

243

### 244 ***hflXr* transcription is regulated by a ribosome-dependent attenuation mechanism**

245 As shown above, *hflXr* expression is induced by lincomycin and erythromycin  
246 (Fig. 1A and 1D). Moreover, *hflXr* is located downstream of *rli80*, a constitutively  
247 transcribed small RNA that we hypothesized to act as a regulatory switch (Fig. 1A).  
248 Using the term-seq data for *L. monocytogenes* grown in the absence of antibiotics[13],  
249 we found an accumulation of 3' reads that occurred immediately downstream of the  
250 *rli80* ribo-regulator, thus suggesting a regulatory mechanism relying on premature  
251 termination[4] (Fig. 1A, black arrow). A hallmark of such ribo-regulators is the ability to  
252 display mutually exclusive RNA folding patterns that either stabilize or destabilize the  
253 transcriptional intrinsic terminator, turning the downstream gene transcription 'off' or  
254 'on', respectively[4, 28, 29]. This process is named "attenuation". We thus searched for

255 such alternative RNA structures in the *rli80* sequence, using the PASIFIC algorithm[30].  
256 We found that *rli80* can indeed fold into either a terminator structure, that would lead to  
257 premature termination and to an accumulation of short RNAs, alternatively in a  
258 structure acting as an anti-terminator, where the terminator is destabilized, allowing the  
259 synthesis of full length *hflXr* mRNA (Fig. 4A and Fig. S8). In addition, we found that *rli80*  
260 encodes a 14 amino-acids upstream open-reading frame (ORF) containing hallmark  
261 signature arginine-leucine-arginine (RLR) motif (Fig. 4A), which is commonly found in  
262 small ORFs of other macrolide sensing attenuators and controls translation arrest by  
263 disturbing the transpeptidation step due to the amino-acid geometry [22], thus  
264 promoting the expression of the downstream macrolide resistance gene[31, 32] (Table  
265 1).

266         Based on this model as well as on the induction by antibiotics, we hypothesized  
267 *hflXr* transcription is controlled either by direct binding of the antibiotic to the mRNA  
268 (riboswitch) or by a ribosome-mediated attenuation mechanism due to ribosomal  
269 stalling on the *rli80* ORF. To discriminate between these two possibilities, we performed  
270 RNA-seq to measure the lincomycin-dependent induction of *hflXr* in a *Listeria* strain  
271 expressing the 23S rRNA methyltransferase ErmC[33]. In these bacteria, the rRNA 23S is  
272 methylated at position A2058, thus rendering the ribosomes insensitive to  
273 lincomycin[33]. The results show that in ErmC-expressing bacteria, the expression of  
274 *lmo0762* was no longer activated in response to the antibiotic (Fig. 4B), suggesting that  
275 the ribo-regulation depends on stalled ribosomes rather than by direct binding of the  
276 antibiotic to the RNA. We further tested this hypothesis by validating that the small ORF  
277 is indeed translated *in-vivo* by generating a translational GFP fusion to the C-terminus of  
278 the small peptide (Fig. 4C), that showed fluorescence when visualised under microscope.  
279 In order to validate the attenuation mechanism, which involves regulatory structures  
280 and the *rli80* ORF, we created a series of mutants. First we mutated the ATG of the ORF  
281 (ATG>ACG), as well as regions that are controlling the formation of the terminator, and  
282 are named anti-terminator region and anti-anti-terminator region (Fig. 4A, brown  
283 dashed squares). We analysed the RNA-seq profile of the *rli80-lmo0762* locus in these  
284 different mutant strains in the absence and presence of lincomycin (Fig. 4D). Strikingly,  
285 and in agreement with the above hypothesis, mutating the anti-terminator region or the  
286 ORF ATG, both of which are predicted to stabilize the 'off' conformation of *rli80*,  
287 prevented the ribo-regulator from activating expression during antibiotic exposure and

288 led to increased antibiotic sensitivity in MIC experiment (Fig S3) and to fewer mRNA  
289 abundance in qRT-PCR assay (Fig. S9). In contrast, mutating the anti-anti-terminator  
290 region, which is predicted to maintain the 'on' conformation of the ribo-regulator, led to  
291 constitutive readthrough and induction of *hflXr*, regardless of the presence of  
292 lincomycin, as well as enhanced antibiotic resistance (Fig 1C, Fig S3 and Fig S9). Taken  
293 together, these results show that *rli80* controls the expression of *hflXr* via a ribosome-  
294 dependent transcription attenuation mechanism, such that HflXr protein expression is  
295 induced in response to ribosome inhibition and stalling.

296

### 297 Discussion

298 In this work, we describe a novel antibiotic resistance mechanism to lincomycin  
299 and erythromycin in *Listeria monocytogenes* which is mediated by Lmo0762, an HflX  
300 homolog, that we renamed HflXr, for HflX-resistance. We showed that deletion of the  
301 gene renders the bacteria more sensitive to erythromycin and lincomycin whilst its  
302 overexpression renders the bacteria more resistant. The induction of the gene in  
303 presence of antibiotics is mediated by an attenuation mechanism that involves a small  
304 ORF containing a RLR sequence. This RLR motif is a signature of macrolide resistance  
305 genes, since it is commonly found in small ORFs in leader regions that regulate their  
306 expression (Table 1) [31, 32]. Moreover, by analysing the ribosome "profiles" of bacteria  
307 grown in presence or absence of antibiotic, we provide evidence that the proportion of  
308 70S ribosome increases upon erythromycin treatment in a strain depleted from *hflXr* in  
309 comparison to the WT strain, which led us to hypothesise that HflXr mechanism of  
310 action is to split ribosomes. Surprisingly, *in vitro* experiments showed that erythromycin  
311 and lincomycin can inhibit the GTPase activity of the *E. coli* HflX[15]. Given that  
312 ribosome splitting was described as a GTP-dependent mechanism[15, 19], further  
313 investigations will be required to reconcile these data with our results.

314

315 Interestingly, *L. monocytogenes* encodes another *hflX* homolog, *lmo1296*, which is  
316 not involved in antibiotic resistance. Many Firmicutes possess two copies of *hflX*  
317 homologs, and similar independent duplications are observed in other clades of  
318 prokaryotes (Fig 2B). Given that many Firmicutes possess a *hflX* gene that belongs to the  
319 sub-family of *hflXr*, it seems reasonable to think that the antibiotic resistance  
320 mechanism that we described in *Listeria* for *hflXr* could be conserved in many other

321 bacteria. This duplication represents an example of how bacteria can employ common  
322 stress response factors as antibiotic resistance genes. In addition, our work is now  
323 strengthened by two studies that were recently published where functional  
324 metagenomic databases constructed from antibiotic rich environments pointed *hflX*  
325 from *Simkania negevensis* and *Emergencia timonensis* as a putative resistance genes [24,  
326 34]. Based on our phylogenetic analysis, *hflX* from *Eubacterium spp*, which is closely  
327 related to *E. timonensis*, belongs to *hflXr* family, which is in agreement with our claim  
328 that this gene family is involved in antibiotic resistance. *S. negevensis* is not a Firmicute  
329 and its *hflX* belongs to sub-families which have not been studied for antibiotic resistance.  
330 These observations reinforce the conclusions of our study and further suggest that this  
331 new antibiotic resistance mechanism is likely spread in the environment. The level of  
332 resistance conferred by *hflXr* which may appear weak in clinical settings according to  
333 EUCAST breakpoints, is probably of importance in the environment and within  
334 microbial communities, conferring resistance to antibiotics that may be found in the soil.

335

336 The benefit provided by *hflXr* in bacteria exposed to lincomycin and to  
337 erythromycin seems different, since it was necessary to delete *lmo0919*, another  
338 lincomycin resistance gene, to observe the effect of the *hflXr* deletion. Lincomycin  
339 belongs to the lincosamide antibiotic family, whose members bind the ribosome at the  
340 peptidyl-transferase center and inhibit peptide bond formation. Erythromycin is a  
341 macrolide antibiotic that also binds at the vicinity of the peptidyl transfer center, in the  
342 peptide exit tunnel channel, nearby to the lincomycin target site. Both antibiotics  
343 prevent translation at early stages of elongation[33]. The remaining stalled ribosomes  
344 need to be recycled in order to start a new round of translation. It is interesting to note  
345 that in order to show the involvement of *lmo0762* in lincomycin resistance, we had to  
346 delete *lmo0919* gene, while the effect of *hflXr* could be directly visualized for  
347 erythromycin. Our careful analysis has shown *lmo0919* gene is encoding an “ABC-F  
348 transporter” (Fig. S10) although we previously considered it encodes an antibiotic efflux  
349 pump. Recent studies have shown that antibiotic resistance genes annotated as “ABC-F  
350 transporters” have the capability of displacing ribosome-bound antibiotics, *in-vitro*[25,  
351 27]. We thus propose that HflXr could act in concert with Lmo0919 in the presence of  
352 lincomycin: HflXr would split the ribosome, while the Lmo0919 would displace the  
353 antibiotic, thus recycling the ribosome to re-start translation. Interestingly, Lmo0919 is

354 only produced in the presence of lincomycin, and is not activated by the presence of  
355 erythromycin[13], while other ABC-F transporters confer macrolide resistance, such as  
356 MsrA[27]. Thus, we hypothesize that in the presence of erythromycin, HflXr acts in  
357 combination with a protein with macrolide displacement activity to rescue stalled  
358 ribosome and restart translation. This hypothesis is presented in Fig. 5.

359

360 *hflX* transcription is regulated by an attenuation mechanism that relies on the  
361 upstream regulatory RNA, rli80, which folds into alternative regulatory structures and  
362 contains a small ORF that harbours the RLR motif. This attenuation mechanism involves  
363 the pausing antibiotic-stalled ribosomes on the ORF, which in turn prevents the  
364 formation of the terminator hairpin structure, thus permitting the transcription the full-  
365 length *hflXr* mRNA. This allows the bacteria to fine-tune the expression of *hflXr* in  
366 response to two antibiotics that block translation after incorporation of few amino acids.  
367 As a consequence, the regulation also works as a feed-forward loop, by shutting down  
368 the expression of HflXr when the antibiotic is cleared. Indeed, in the absence of drug, the  
369 ribosome does not pause on the regulatory region, and this in turn prevent *hflXr*  
370 transcription. These findings are recapitulated in our model (Fig. 5). Such an attenuation  
371 mechanism involving RNA structures and a small ORF has been found for different  
372 antibiotic resistance genes e.g. *ermC* gene[4, 31]. It is interesting to note that in this  
373 latter example, a translation attenuation modulates the availability of the ribosome  
374 binding site of the resistance gene, whilst our regulation mechanism modulates the  
375 transcription of *lmo0762* via a transcriptional attenuation.

376

377 Overall, we described here a novel antibiotic resistance mechanism in *Listeria*  
378 *monocytogenes*, that uses HflXr protein to recycle ribosomes in presence of antibiotics.  
379 The gene *hflXr* seems widely spread across species, and it is to be expected that *hflXr*  
380 genes will be employed in other bacteria species for antibiotic resistance in the  
381 environment and within bacterial communities. This study also allows us to highlight  
382 how bacteria can take advantage of general stress factors e.g., a heat shock factor, by  
383 using them in a different context, in order to improve fitness and growth in a broad  
384 range of conditions.

385

386 Materials and Methods

387

388 Materials and Methods can be found in the Supplementary Information sheet.

389

390 Acknowledgments

391 We sincerely thank our referees, their comments have dramatically increased the quality  
392 of this article. We thank Stefano Marzi and Pascale Romby for advices and hosting in the  
393 laboratory, and Claire Poyart, Grégory Boël, and Olivier Dussurget for useful discussions.  
394 We thank Nora Vazquez-Laslop for critical inputs on the article. We thank Laurence  
395 Maranghi, Julienne Blondou and Youssouf Boina for essential technical support.

396 This work was supported, in part, by grants to P.C. (European Research Council (ERC)  
397 Advanced Grant BacCellEpi (670823), ANR BACNET (BACNET 10-BINF-02-01), ANR  
398 Investissement d'Avenir Programme (10-LABX-62-IBEID), Human Frontier Science  
399 Program (HFSP; RGP001/2013), ERANET Infect-ERA PROANTILIS (ANR-13-IFEC-0004-  
400 02) and the Fondation le Roch les Mousquetaires) ; and, in part, by grants to R.S (Israel  
401 Science Foundation personal grant (1360/16) and I-CORE grant (1796/12), European  
402 Research Council (ERC) grant (ERC-CoG 681203), the German Research Council priority  
403 program SPP 2002 (grant SO 1611/1-1) and the Pasteur-Weizmann council). P.C. is a  
404 Senior International Research Scholar of the Howard Hughes Medical Institute.

405

406 References

- 407 1. Chandra N, Kumar S (2017) Antibiotics Producing Soil Microorganisms. In:  
408 Hashmi MZ, Strezov V, Varma A (eds) Antibiotics and Antibiotics Resistance Genes  
409 in Soils: Monitoring, Toxicity, Risk Assessment and Management. Springer  
410 International Publishing, Cham, pp 1–18
- 411 2. Cox G, Wright GD (2013) Intrinsic antibiotic resistance: Mechanisms, origins,  
412 challenges and solutions. *Int J Med Microbiol* 303:287–292 . doi:  
413 10.1016/j.ijmm.2013.02.009
- 414 3. Blair JMA, Webber MA, Baylay AJ, et al (2015) Molecular mechanisms of antibiotic  
415 resistance. *Nat Rev Microbiol* 13:42–51 . doi: 10.1039/c0cc05111j
- 416 4. Dar D, Sorek R (2017) Regulation of antibiotic-resistance by non-coding RNAs in  
417 bacteria. *Curr Opin Microbiol* 36:111–117 . doi: 10.1016/j.mib.2017.02.005
- 418 5. Cossart P, Lebreton A (2014) A trip in the “New Microbiology” with the bacterial  
419 pathogen *Listeria monocytogenes*. *FEBS Lett* 588:2437–2445 . doi:

- 420 10.1016/j.febslet.2014.05.051
- 421 6. Noll M, Kleta S, Al Dahouk S (2017) Antibiotic susceptibility of 259 *Listeria*  
422 *monocytogenes* strains isolated from food, food-processing plants and human  
423 samples in Germany. *J Infect Public Health*. doi: 10.1016/j.jiph.2017.12.007
- 424 7. Wu S, Wu Q, Zhang J, et al (2015) *Listeria monocytogenes* prevalence and  
425 characteristics in retail raw foods in China. *PLoS One* 10:1–16 . doi:  
426 10.1371/journal.pone.0136682
- 427 8. Yadav MM, Roy A, Bhandari B (2018) Multiple Antibiotic Resistance among  
428 *Listeria* Strains , Including *Listeria monocytogenes* Isolated from Animals of  
429 Gujarat State , India. *IntJCurrMicrobiolAppSci* 7:1493–1501
- 430 9. Roberts MC, Facinelli B, Giovanetti E, Varaldo PE (1996) Transferable  
431 erythromycin resistance in *Listeria* spp. isolated from food. *Appl Environ*  
432 *Microbiol* 62:269–70
- 433 10. Charpentier E, Courvalin P (1997) Emergence of the trimethoprim resistance gene  
434 *dfrD* in *Listeria monocytogenes* BM4293. *Antimicrob Agents Chemother* 41:1134–  
435 6
- 436 11. Walsh D, Duffy G, Sheridan JJ, et al (2001) Antibiotic resistance among *Listeria*,  
437 including *Listeria monocytogenes*, in retail food. *J Appl Microbiol* 90:517–522 .  
438 doi: 10.1046/j.1365-2672.2001.01273.x
- 439 12. Poyart-Salmeron C, Carlier C, Trieu-Cuot P, et al (1990) Transferable plasmid-  
440 mediated antibiotic resistance in *Listeria monocytogenes*. *Lancet* (London,  
441 England) 335:1422–1426 . doi: 10.1016/0140-6736(90)91447-I
- 442 13. Dar D, Shamir M, Mellin JR, et al (2016) Term-seq reveals abundant ribo-  
443 regulation of antibiotics resistance in bacteria. *Science* (80- ) 352:1–12 . doi:  
444 10.1126/science.aad9822
- 445 14. Wilson DN (2014) Ribosome-targeting antibiotics and mechanisms of bacterial  
446 resistance. *Nat Rev Microbiol* 12:35–48 . doi: 10.1038/nrmicro3155
- 447 15. Coatham ML, Brandon HE, Fischer JJ, et al (2015) The conserved GTPase HflX is a  
448 ribosome splitting factor that binds to the E-site of the bacterial ribosome. *Nucleic*  
449 *Acids Res* 44:1952–1961 . doi: 10.1093/nar/gkv1524
- 450 16. Polkinghorne A, Ziegler U, González-Hernández Y, et al (2008) *Chlamydomonas*  
451 *pneumoniae* HflX belongs to an uncharacterized family of conserved GTPases and  
452 associates with the *Escherichia coli* 50S large ribosomal subunit. *Microbiology*



- 453 154:3537–3546 . doi: 10.1099/mic.0.2008/022137-0
- 454 17. Jain N, Dhimole N, Khan AR, et al (2009) E. coli HflX interacts with 50S ribosomal  
455 subunits in presence of nucleotides. Biochem Biophys Res Commun 379:201–205 .  
456 doi: 10.1016/j.bbrc.2008.12.072
- 457 18. Dutta D, Bandyopadhyay K, Datta AB, et al (2009) Properties of HflX, an enigmatic  
458 protein from escherichia coli. J Bacteriol 191:2307–2314 . doi: 10.1128/JB.01353-  
459 08
- 460 19. Zhang Y, Mandava CS, Cao W, et al (2015) HflX is a ribosome-splitting factor  
461 rescuing stalled ribosomes under stress conditions. Nat Struct Mol Biol 22:1–11 .  
462 doi: 10.1038/nsmb.3103
- 463 20. Basu A, Yap M-NF (2017) Disassembly of the *Staphylococcus aureus* hibernating  
464 100S ribosome by an evolutionarily conserved GTPase. Proc Natl Acad Sci  
465 201709588 . doi: 10.1073/pnas.1709588114
- 466 21. Dey S, Biswas C, Sengupta J (2018) The universally conserved GTPase HflX is an  
467 RNA helicase that restores heat-damaged Escherichia coli ribosomes. J Cell Biol  
468 217:1–11
- 469 22. Vázquez-Laslop N, Mankin AS (2018) How Macrolide Antibiotics Work. Trends  
470 Biochem Sci xx:1–17 . doi: 10.1016/j.tibs.2018.06.011
- 471 23. Balestrino D, Anne Hamon M, Dortet L, et al (2010) Single-cell techniques using  
472 chromosomally tagged fluorescent bacteria to study *Listeria monocytogenes*  
473 infection processes. Appl Environ Microbiol 76:3625–3636 . doi:  
474 10.1128/AEM.02612-09
- 475 24. Lau CH-F, Van Engelen K, Gordon S, et al (2017) Novel antibiotic resistant gene  
476 from agricultural soil exposed to antibiotics widely used in human medicine and  
477 animal farming. Appl Environ Microbiol 83:1–18 . doi: 10.1128/AEM.00989-17
- 478 25. Sharkey L, Edwards T, O’Neill A (2016) ABC-F Proteins Mediate Antibiotic  
479 Resistance through Ribosomal Protection. MBio 7:1–10 . doi:  
480 10.1128/mBio.01975-15.Editor
- 481 26. Thaker M, Spanogiannopoulos P, Wright GD (2010) The tetracycline resistome.  
482 Cell Mol Life Sci 67:419–431 . doi: 10.1007/s00018-009-0172-6
- 483 27. Sharkey LKR, O’Neill AJ (2018) Antibiotic Resistance ABC-F Proteins: Bringing  
484 Target Protection into the Limelight. ACS Infect Dis 4:239–246 . doi:  
485 10.1021/acsinfecdis.7b00251

- 486 28. Yanofsky C (1981) Attenuation in the control of expression of bacterial operons.  
487 Nature 289:751–758 . doi: 10.1038/289751a0
- 488 29. Merino E, Yanofsky C (2005) Transcription attenuation: A highly conserved  
489 regulatory strategy used by bacteria. Trends Genet 21:260–264 . doi:  
490 10.1016/j.tig.2005.03.002
- 491 30. Millman A, Dar D, Shamir M, Sorek R (2017) Computational prediction of  
492 regulatory, premature transcription termination in bacteria. Nucleic Acids Res  
493 45:886–893 . doi: 10.1093/nar/gkw749
- 494 31. Ramu H, Mankin A, Vazquez-Laslop N (2009) Programmed drug-dependent  
495 ribosome stalling: MicroReview. Mol Microbiol 71:811–824 . doi: 10.1111/j.1365-  
496 2958.2008.06576.x
- 497 32. Sothiselvam S, Liu B, Han W, et al (2014) Macrolide antibiotics allosterically  
498 predispose the ribosome for translation arrest. Proc Natl Acad Sci 111:9804–9809  
499 . doi: 10.1073/pnas.1403586111
- 500 33. Wilson DN (2009) The A-Z of bacterial translation inhibitors. Crit Rev Biochem  
501 Mol Biol 44:393–433 . doi: 10.3109/10409230903307311
- 502 34. González-Plaza JJ, Šimatovic A, Milakovic M, et al (2018) Functional Repertoire of  
503 Antibiotic Resistance Genes in Antibiotic Manufacturing Effluents and Receiving  
504 Freshwater Sediments. Front Microbiol 8:1–13 . doi: 10.3389/fmicb.2017.02675

505

506

507 Figure Legends

508

509 **Figure 1. Lmo0762 expression is induced in the presence of lincomycin and**  
510 **erythromycin.** (A) *L. monocytogenes* was grown until exponential phase in BHI, and  
511 bacteria were collected before (black RNA-seq coverage), or after 15 min exposure to  
512 sub-inhibitory concentration (0.25 µg/ml) of lincomycin (green). The RNA was  
513 extracted and sequenced, and the result for *rli80-lmo0762* is shown here. RNA-seq  
514 coverage was normalized by the number of uniquely mapped reads in each sequencing  
515 library. Black and green curves represent RNA-seq coverage, black arrow represents  
516 term-seq reads. (B) Bacteria EGDe WT and carrying a flag tag at the C-terminus of  
517 Lmo0762 (Flag) were grown for 1h in presence or in absence of various concentrations  
518 of lincomycin and erythromycin, and total protein were extracted. Western blot analysis

519 using anti-flag antibody revealed an induction of Lmo0762-flag in presence of the  
520 antibiotic. EF-Tu was used as a loading control. (C) Schematic representation of MIC  
521 experiment. The colors indicates that the tested strain is more sensible (blue) or more  
522 resistant (red) to the antibiotic compared to the reference (ref) strain. Lmo0762  
523 induction is also represented. (D) RNA was extracted from wild-type bacteria grown in  
524 BHI, before and after 15 min exposure to lincomycin or erythromycin. Induction of  
525 *lmo0762* and *lmo1296* was calculated by comparison with their endogenous level before  
526 the addition of the antibiotic. Data are represented as mean  $\pm$  s.e.m. We used a one-way  
527 anova on  $\Delta$ Ct values for statistics, using biological replicates as pairing factors ( $p < 0.05$ ).

528

529 **Figure 2. Phylogeny of HflX homologs.** (A) Schematic representation of MIC  
530 experiments, similar to 1C. (B) Schematic representation of the phylogenetic tree of *hflX*  
531 homologs among prokaryotes. A detailed tree is available on Fig. S4, S5 and on  
532 additional on-line file S1.

533

534 **Figure 3. Lmo0762 is involved in recycling of antibiotic-stalled 70S ribosomes.**  
535 Wild-type (blue) and  $\Delta$ *lmo0762* (purple) bacteria were grown in BHI medium until  
536 exponential phase and erythromycin (0.18  $\mu$ g/ml) was added or not for 1h.  
537 Chloramphenicol was then added to the culture (2 min exposure at 5 mM) in order to  
538 stabilize the polysomes, and bacteria were pelleted and flash-frozen. The cellular  
539 content was extracted, and 15K units of  $A_{260nm}$  was loaded on a 5-50% sucrose gradient.  
540 After ultracentrifugation, the samples were collected from top (0mm) to bottom  
541 (80mm) of the tubes and the  $A_{260nm}$  absorbance was monitored using a UV lamp. The  
542 baseline was corrected and the results were normalized based on the area under the  
543 curve.

544

545 **Figure 4. Lmo0762 expression is regulated by a transcription attenuation**  
546 **mechanism.** (A) The predicted rli80 RNA-structures were analysed using the PASIFIC  
547 algorithm, and two alternative conformations were predicted, one with an intrinsic  
548 terminator (left) that leads to a short transcript, and one with an anti-terminator (right)  
549 that leads to a long transcript that encodes *lmo0762*. Key regulatory regions were  
550 identified (anti-anti-terminator in red, anti-terminator in orange, terminator in  
551 green/blue) and a short ORF of 14 amino acids (purple) is encoded in a region that

552 encompasses the anti-anti-terminator region. Different mutants were created where  
553 regulatory regions were removed (dashed brown squares) in order to decipher the  
554 regulatory mechanism. (B) Wild-type bacteria in which *ermC* expression was induced or  
555 not were grown as described in the legend to figure 1A and RNA was extracted and  
556 sequenced. The RNA-seq profile of the *rli80-lmo0762* locus is presented here. (C) The *L.*  
557 *monocytogenes lmo0762* ribo-regulator (*rli80*) was modified by a chromosomal in-frame  
558 fusion of a GFP reporter protein that lacks the initiation codon, to the 14 aa ORF. Left  
559 and right panels show the phase contrast and fluorescence images, respectively, and  
560 demonstrate that the ORF is translated *in-vivo*. (D) Wild-type and mutant bacteria were  
561 grown as described in the legend to figure 1A and RNA was extracted. The RNA-seq  
562 profile of the *rli80-lmo0762* locus is presented here.

563

564 **Figure 5. Model of the combined action of Lmo0762 and Lmo0919 to protect**  
565 **bacteria against lincomycin and erythromycin.**





566

567

568 **Table 1. RLR motif is found upstream of macrolide resistance genes.** Many  
569 macrolide resistance genes are located downstream a small ORF which contains the RLR  
570 motif. We selected few examples of these genes (list modified from[31]), a complete list  
571 is available in[32]

572

573




A

ery


WT

 $\Delta$ Imo1296 $\Delta$ Imo0762 $\Delta$ Imo1296 $\Delta$ Imo0762 $\Delta$ Imo0762-cpt $\Delta$ Imo0762-cpt1296


B




Erythromycin



A




B



C





D







no antibiotics



 no HflXr production

+ lincomycin 



+ erythromycin 